RCS - OptiBiotix Health - New commercialisation partner in Asia Pacific

OptiBiotix HealthAnnouncement

14/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220914:nRSN3219Za&default-theme=true

RNS Number : 3219Z  OptiBiotix Health PLC  14 September 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

New commercialisation partner in Asia Pacific

 

OptiBiotix Ltd, a wholly owned subsidiary of OptiBiotix Health plc (AIM: OPTI)
and a life sciences business developing patented science and human study-based
compounds that modulate the microbiome to address a range of health related
issues such as metabolic syndrome and diabetes, systemic low-grade
inflammation, obesity, cardiovascular disease, high cholesterol and healthy
aging announces it has signed a services agreement with Nutraconnect for the
Asia Pacific ("APAC") Region. Nutraconnect will develop and implement the
go-to-market strategy for prebiotics ingredients SlimBiome® and LeanBiome®.

 

Nutraconnect Pte., Ltd. ("Nutraconnect"), is a nutraceutical business growth
acceleration service headquartered in Singapore. The company provides
end-to-end solutions for global nutraceutical ingredient manufacturers that
are looking to establish a foundation for sustainable growth in the fragmented
but growing APAC market. Nutraconnect possesses a wealth of experience in
bringing innovative and science backed nutraceutical ingredients successfully
to the market in the region.

 

René Kamminga, CEO of OptiBiotix Limited, commented: "Nutraconnect is an
important extension of our commercial experience and reach in the APAC region.
Nutraconnect brings unique regulatory and commercial experience combined with
an extensive distribution and agency network in the various countries in the
region. This partnership will help expedite the commercialisation of our
prebiotic technologies in strategic countries in the region. At the same time,
it will allow OptiBiotix to focus primarily on established key accounts and
building up our North American presence and sales."

 

The Directors of the Company are responsible for the release of this
announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                               www.optibiotix.com (http://www.optibiotix.com/)
 Stephen O'Hara, Chief Executive     Contact via Walbrook below

 Cenkos Securities plc (Broker)                      Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                     Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com)

 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABKNBQQBKDBCD